Bloom Burton analyst Prasath Pandurangan maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) today and set a price target of $49.00. The company's shares closed last Friday at $20.46, close to its 52-week low of $19.82. According to TipRanks.com, Pandurangan is a 1-star analyst with an average return of -2.3% and a 33.3% success rate. Pandurangan covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Trillium Therapeutics, and Knight Therapeutics. Repare Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $48.17, a 135.4% upside from current levels. In a report released today, Berenberg Bank also reiterated a Buy rating on the stock with a $51.00 price target. See today’s analyst top recommended stocks >> Based on Repare Therapeutics' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $279K and GAAP net loss of $26.31 million. In comparison, last year the company had a GAAP net loss of $11.8 million. Based on the recent corporate insider activity of 209 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RPTX in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. Read More on RPTX: Merck Stock: Pharmaceutical Giant Shows Promise Deere’s Employees Vote Against Tentative Agreements Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Xenon (XENE) and Kinnate Biopharma (KNTE) Oshkosh Expects Supply Chain Drags to Lower Q4 Revenues Tyra Bioscience, Inc (TYRA) Receives a Buy from Jefferies The post Repare Therapeutics (RPTX) Gets a Buy Rating from Bloom Burton appeared first on TipRanks Financial Blog.